Japan Hereditary Testing Market Size & Outlook, 2025-2033

The hereditary testing market in Japan is expected to reach a projected revenue of US$ 3,413.3 million by 2033. A compound annual growth rate of 15.7% is expected of Japan hereditary testing market from 2025 to 2033.
Revenue, 2024 (US$M)
$948.7
Forecast, 2033 (US$M)
$3,413.3
CAGR, 2025 - 2033
15.7%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan hereditary testing market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan hereditary testing market highlights

  • The Japan hereditary testing market generated a revenue of USD 948.7 million in 2024 and is expected to reach USD 3,413.3 million by 2033.
  • The Japan market is expected to grow at a CAGR of 15.7% from 2025 to 2033.
  • In terms of segment, hereditary non-cancer testing was the largest revenue generating disease type in 2024.
  • Hereditary Non-cancer Testing is the most lucrative disease type segment registering the fastest growth during the forecast period.


Hereditary testing market data book summary

Market revenue in 2024USD 948.7 million
Market revenue in 2033USD 3,413.3 million
Growth rate15.7% (CAGR from 2025 to 2033)
Largest segmentHereditary non-cancer testing
Fastest growing segmentHereditary Non-cancer Testing
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationHereditary Cancer Testing, Hereditary Non-cancer Testing
Key market players worldwideMyriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 5.9% of the global hereditary testing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China hereditary testing market is projected to lead the regional market in terms of revenue in 2033.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,820.3 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hereditary Testing Market Companies

Name Profile # Employees HQ Website
MedGenome View profile 501-1000 Bangalore, Karnataka, India, Asia https://diagnostics.medgenome.com
Twist Bioscience Corp View profile 919 681 Gateway Boulevard, South San Francisco, CA, United States, 94080 https://www.twistbioscience.com
Sophia Genetics SA View profile 449 La Pièce 12, Rolle, Switzerland, CH-1180 https://www.sophiagenetics.com
CooperSurgical View profile 501-1000 Trumbull, Connecticut, United States, North America http://www.coopersurgical.com
Fulgent Genetics Inc View profile 1012 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 https://www.fulgentgenetics.com
Centogene NV Ordinary Shares View profile 493 Am Strande 7, Rostock, MV, Germany, 18055 https://www.centogene.com
Labcorp Holdings Inc View profile 67000 358 South Main Street, Burlington, NC, United States, 27215 https://www.labcorp.com
Invitae Corp View profile 1700 1400 16th Street, San Francisco, CA, United States, 94103 https://www.invitae.com
The Cooper Companies Inc View profile 15000 6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, United States, 94583 https://www.coopercos.com
Natera Inc View profile 3293 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 https://www.natera.com
Myriad Genetics Inc View profile 2700 320 Wakara Way, Salt Lake City, UT, United States, 84108 https://www.myriad.com
Agilent Technologies Inc View profile 17700 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 https://www.agilent.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Quest Diagnostics Inc View profile 48000 500 Plaza Drive, Secaucus, NJ, United States, 07094 https://www.questdiagnostics.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

Japan hereditary testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.


Hereditary non-cancer testing was the largest segment with a revenue share of 79.9% in 2024. Horizon Databook has segmented the Japan hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2021 to 2033.


Continuous product developments pertaining to hereditary testing of cancer and noncancer medical conditions in Japan result in its major revenue share in Asia Pacific market. In November 2019, Myriad Genetics, Inc. received approval from Ministry of Health, Labour and Welfare (MHLW), Japan, for BRACAnalysis Diagnostic System.

The system is expected to assist physicians in determining risk of hereditary breast and ovarian cancers in women. It is a genetic test that determines germline mutations in BRCA1/BRCA2 genes. The approval further validated risk assessment in Japanese breast cancer patients. 

Myriad, in partnership with SRL Inc., a subsidiary of Miraca Group, markets BRACAnalysis Diagnostic System in Japan. Apart from product development, Japanese government is undertaking several efforts to reinforce the noninvasive prenatal genetic testing in this region.

Reasons to subscribe to Japan hereditary testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan hereditary testing market databook

  • Our clientele includes a mix of hereditary testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Japan hereditary testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan hereditary testing market size, by disease type, 2021-2033 (US$M)

Japan Hereditary Testing Market Share, 2024 & 2033 (US$M)

Japan hereditary testing market size, by disease type, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online